{"id":2660,"date":"2019-12-05T16:13:09","date_gmt":"2019-12-05T21:13:09","guid":{"rendered":"http:\/\/localhost:10028\/whitepapers\/hunter-shkolnik-comments-on-proposed-opioid-settlement\/"},"modified":"2022-06-27T02:34:55","modified_gmt":"2022-06-27T06:34:55","slug":"%e3%83%8f%e3%83%b3%e3%82%bf%e3%83%bc-shkolnik-comments-on-proposed-opioid-settlement","status":"publish","type":"whitepapers","link":"https:\/\/napolilaw.lemonadestand.org\/ja\/%e7%99%bd%e3%81%84%e7%b4%99\/%e3%83%8f%e3%83%b3%e3%82%bf%e3%83%bc-shkolnik-comments-on-proposed-opioid-settlement\/","title":{"rendered":"\u30cf\u30f3\u30bf\u30fc\u30fb\u30b7\u30e5\u30b3\u30eb\u30cb\u30af\u3001\u63d0\u6848\u3055\u308c\u305f\u30aa\u30d4\u30aa\u30a4\u30c9\u548c\u89e3\u306b\u3064\u3044\u3066\u30b3\u30e1\u30f3\u30c8"},"content":{"rendered":"<p>Teva Pharmaceutical Industries Ltd.&#8217;s proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.<\/p>\n<p>The deal is &#8220;overvalued to make the settlement look better,&#8221; said Hunter Shkolnik, a lawyer on the plaintiffs executive committee that is managing more than 2,300 federal lawsuits consolidated in the U.S. District Court in Cleveland.<\/p>\n<p>&#8220;I don&#8217;t believe a no-cash payment from Teva, one of the largest generic manufacturers in the world, is appropriate,&#8221; he told Reuters.<\/p>\n<p>Israel-based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers, together with drugmaker Johnson &amp; Johnson and the three largest U.S. drug distributors, AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.<\/p>","protected":false},"excerpt":{"rendered":"<p>Teva Pharmaceutical Industries Ltd. \u304c\u63d0\u6848\u3057\u305f $230 \u5104\u306e\u533b\u85ac\u54c1\u306e\u30d7\u30ec\u30bc\u30f3\u30c8\u306f\u3001\u7c73\u56fd\u306e\u6570\u5343\u4ef6\u306e\u30aa\u30d4\u30aa\u30a4\u30c9\u8a34\u8a1f\u3092\u89e3\u6c7a\u3059\u308b\u305f\u3081\u306b\u3001\u305d\u306e\u91d1\u984d\u306e\u4f55\u5206\u306e 1 \u304b\u306e\u8cbb\u7528\u3067\u6e08\u3080\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>","protected":false},"featured_media":0,"menu_order":224,"template":"","whitepaper_category":[57,75,98,253,254],"whitepaper-source":[337],"class_list":["post-2660","whitepapers","type-whitepapers","status-publish","hentry","whitepaper_category-hunter-shkolnik","whitepaper_category-opioids-litigation","whitepaper_category-ohio-opioid-lawyers","whitepaper_category-opioid-crisis","whitepaper_category-opioid-epidemic","whitepaper-source-daily-stock-dish"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/whitepapers\/2660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/whitepapers"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/types\/whitepapers"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/whitepapers\/2660\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/media?parent=2660"}],"wp:term":[{"taxonomy":"whitepaper_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/whitepaper_category?post=2660"},{"taxonomy":"whitepaper-source","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/ja\/wp-json\/wp\/v2\/whitepaper-source?post=2660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}